AstronauTx
AstronauTx was created in 2019 with the goal of developing novel drugs to correct the disrupted physiology of the brain. Brandon is a Series A investor with the company using the funding to advance the company’s portfolio of first-in-class, small-molecule drugs, including a clinical study in patients with Alzheimer’s disease for its lead program.
Therapeutic Area:
Alzheimer’s DiseaseNeurodegenerationNeuroscience
$61M
Funding: Series A 2023
2019
Year Founded
Unmet Need and Commercial Potential
Over 55 million people globally suffer from dementia, with Alzheimer’s disease being the most common form. Current treatments offer limited benefit; AstronauTx’s approach could revolutionise care by modifying disease progression and alleviating symptoms—offering hope for millions of patients and caregivers.
55M+
People with Dementia
Advancing astrocyte biology to treat Alzheimer's disease
Syndicate investors
